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Abstract
Background: Cigarette smoking is an important risk factor for pulmonary arterial hypertension (PAH) in chronic
obstructive pulmonary disease (COPD). Chymase has been shown to function in the enzymatic production of
angiotensin II (AngII) and the activation of transforming growth factor (TGF)-b1 in the cardiovascular system. The
aim of this study was to determine the potential role of chymase in cigarette smoke-induced pulmonary artery
remodeling and PAH.
Methods: Hamsters were exposed to cigarette smoke; after 4 months, lung morphology and tissue biochemical
changes were examined using immunohistochemistry, Western blotting, radioimmunoassay and reverse-
transcription polymerase chain reaction.
Results: Our results show that chronic cigarette smoke exposure significantly induced elevation of right ventricular
systolic pressures (RVSP) and medial hypertrophy of pulmonary arterioles in hamsters, concurrent with an increase
of chymase activity and synthesis in the lung. Elevated Ang II levels and enhanced TGF-b1/Smad signaling
activation were also observed in smoke-exposed lungs. Chymase inhibition with chymostatin reduced the cigarette
smoke-induced increase in chymase activity and Ang II concentration in the lung, and attenuated the RVSP
elevation and the remodeling of pulmonary arterioles. Chymostatin did not affect angiotensin converting enzyme
(ACE) activity in hamster lungs.
Conclusions: These results suggest that chronic cigarette smoke exposure can increase chymase activity and
expression in hamster lungs. The capability of activated chymase to induce Ang II formation and TGF-b1 signaling
may be part of the mechanism for smoking-induced pulmonary vascular remodeling. Thus, our study implies that
blockade of chymase might provide benefits to PAH smokers.
Background
Pulmonary arterial hypertension (PAH) results from a
variety of initiating stimuli. Cigarette smoking is an
important risk factor for PAH which is frequently devel-
oped in patients with severe chronic obstructive pul-
monary disease (COPD) [1,2]. The pathogenesis of PAH
in smokers is still unclear. In animal models, chronic
smoke exposure could cause muscle cell proliferation in
small intrapulmonary arteries and induce inflammatory
cell influx into the lung, releasing numerous mediators
that control the remodeling of pulmonary vessels [3,4].
Chymase, a chymotrypsin-like serine protease which is
mainly contained in the secretory granules of the mast
cells, has recently been implicated in vascular diseases
[5,6]. Like angiotensin-converting enzyme (ACE), chy-
mase is capable of generating angiotensin II (Ang II)
from angiotensin I (Ang I). Greater than 80% of Ang II
formation in the human heart and greater than 60% in
arteries appears to result from chymase activity [7], and
chymase-dependent Ang II may have an important role
in human cardiovascular system function [8]. Upon sti-
mulations, e.g. vascular injury, mast cells-released
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chymase can promote vascular proliferation, athero-
sclerosis, organ remodeling, and tissue fibrosis [6,9]. In
monocrotaline-induced PAH rats, Ang II-forming chy-
mase was found to increase pulmonary arteriolar hyper-
trophy and pulmonary hypertension [10]. Moreover,
chymase has recently been reported to induce profibro-
tic response via transforming growth factor (TGF)-b1/
Smad signaling activation [11,12]. Chymase blockade
with inhibitors can suppress bleomycin-induced pul-
monary fibrosis in hamsters and mice [13,14]. In clinical
studies, accumulation of chymase-expressing mast cells
is strongly associated with increased vascularity in air-
way mucosa of asthmatic patients [15]. In smokers,
expiratory lung attenuation (Hounsfield units) measured
by quantitative computed tomography (CT) analysis cor-
relates negatively with chymase-positive mast cell infil-
tration in the smooth muscle layer of peripheral airways
[16]. In addition, mast cell non-uniform distribution
throughout the bronchial tree suggests its involvement
in the development of smoking-related peripheral lung
injury [17]. However, it still remains unknown whether
chymase is involved in cigarette smoke-induced pul-
monary artery remodeling and PAH.
The role of chymase in generating Ang II differs
among different species. Hamster chymase, like human
chymase, is a highly efficient ANG II-forming enzyme
[18]. Therefore, in this study, we used hamsters to
examine the potential pathophysiological role of chy-
mase in lung vascular remodeling and PAH induced by
smoke exposure and to discuss the underlying mechan-
isms. Our results imply for the first time that chymase
may have a role in cigarette smoke-induced pulmonary
artery remodeling and pulmonary hypertension in ham-
sters, possibly through the induction of both Ang II
formation and TGF-b1/Smad signaling pathway
activation.
Methods
Smoke exposure and animal treatment
One-month-old male hamsters, weighing 80-100 g were
obtained from the Wu Han Institute of Biological Pro-
ducts (Wu Han, China). All experimental protocols were
approved by the Institutional Animal Care and Use
Committee of Sichuan University (Chengdu, China).
Hamsters (n = 6/group) were exposed to the whole
smoke from 15 commercial nonfilter cigarettes (Wuniu,
14 mg of tar and 1 mg of nicotine per cigarette,
Chengdu Cigarette Factor, Chengdu, China) in venti-
lated whole body exposure chambers (70 × 50 × 50 cm;
with a small electric fan inside for chamber mixing) for
30 min each time, twice per day for up to four months
with minor modifications as previously described [19].
The smoke total particulate matter (TPM) concentration
inside the exposure chambers was 250 ± 26 mg/m3,
determined by gravimetric analysis of filters at the
exhaust port for the duration of the exposure. Hamsters
in control groups were exposed to filtered fresh air
under similar conditions.
Chymostatin (1 mg/kg and 2 mg/kg) or distilled saline
was administered in a volume of 100 μl by intraperito-
neal injection to hamsters 0.5 h before the first smoke
exposure each day.
Hemodynamic analysis
At the end of four months of smoke exposure, right
ventricular systolic pressure (RVSP) was recorded. The
hamsters were anesthetized with pentobarbitone (50
mg/kg i.p.), and placed in the supine position. An intro-
ducer connected to an artery catheter was punctured
into the right jugular vein and then into the right ventri-
cle under pressure waveform monitoring. After a period
of stabilization, RVSP were recorded using a miniature
pressure transducer (Biopac Systems, USA) and a com-
puterized data-acquisition system (MP150; Biopac
Systems).
Histological analysis and tissue preparation
After the animals were sacrificed by carotid artery
exsanguination, the left main-stem bronchus was ligated,
and 4% polyformaldehyde (pH 7.4) was instilled into the
right lung through the trachea under constant pressure
(20 cmH2O) for 30 min, and then the right lung was
removed and submersed in the same fixative overnight
at room temperature for paraffin embedding, sectioning
and histological staining. The remainder of the lung was
dissected, and snap-frozen in liquid nitrogen, then
stored at -80°C for biochemical analysis.
The Paraffin sections (4 μm thick) were stained with
hematoxylin and eosin (H&E), Masson’s trichrome stain
and van Gieson’s elastic stain. For assessment of vascu-
lar morphology, the medial wall thickness (MWT) in
fully muscularized arteries with an external diameter of
50 to 100 μm was evaluated by calculating the percen-
tage of medial wall thickness as (medial thickness × 2/
external diameter) × 100% along the shortest curvature
[10,20]. The external vessel diameter is the distance
within external elastic lamella, and the medial thickness
is the distance between external and internal elastic
laminae. At least 10 muscular arteries per section, 30
arteries per animal were examined using Image Plus 5.0
System (Media Cybernetics, Silver Spring, USA) in a
blinded fashion by a skilled investigator.
For the immunohistochemical detection of chymase,
the sections were stained with mouse monoclonal anti-
body to human chymase (1:1000; Chemicon, Temecula,
USA) using the VECTASTAIN ABC kit (Vector Labora-
tories, Burlingame, USA). Preliminary experiments indi-
cated that microwaving for 15 min in 0.01 M citric acid
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buffer (pH 6.0) [21] was necessary to unmask epitopes
for the anti-chymase antibody.
Measurement of Ang II levels, chymase and ACE activities
Tissue Ang II levels were measured by iodine-125 radio-
immunoassay (RIA) using the Ang II RIA kit (Beijing
North Institute of Biological Technology, Beijing, China)
according to the manufacture’s instructions [22]. Briefly,
lung tissue was washed with cold saline, minced and
heated in 0.1 M HCl at 100°C for 10 min, then homoge-
nized. After centrifugation at 15,000 g for 30 min, the
supernatant was lyophilized and redissolved in 400 μl
assay buffer, and the radioactivity was measured by a g
counter.
Chymase-like and ACE activities in the lung were also
determined by RIA as previously described [22]. Briefly,
lung tissue was homogenized in 20 mM cold Tris-HCl
(pH 7.4) buffer. Protein concentration was determined
using the bicinchoninic acid (BCA) assay (Pierce, Rock-
ford, IL, USA). The serine protease inhibitor aprotinin
(Sigma) and the ACE inhibitor lisinopril (Sigma) were
used to inhibit proteases other than chymase. The reac-
tions for each sample were divided into three groups,
each containing enzyme preparation and 6 ng Ang I as
in group one, while 50 μM lisinopril was added in
group two and 20 μM aprotinin, 20 mM EDTA plus 50
μM lisinopril were added in group three. A blank con-
trol (without sample) was set up for each group. The
reaction (total volume 500 μl) was initiated by adding
20 μl of sample followed by incubation at 37°C for 15
min and terminated by adding 2.5 volumes (1.3 ml) of
ethanol. After centrifugation at 15 000 g for 30 min, the
supernatant was lyophilized and redissolved in the assay
buffer provided by the Ang I RIA kit (Beijing North
Institute of Biological Technology, Beijing, China) and
counted for radioactivity. The enzymatic activities were
determined based on the decrease of Ang I. One unit
(U) of activity was defined as the amount of enzyme
producing 1 ng Ang I decrease per min. The activity not
inhibited in the presence of lisinopril, aprotinin and
EDTA was considered to be chymase-like activity and
the activity inhibited by lisinopril was considered to be
ACE activity.
RNA Isolation and reverse-transcription polymerase chain
reaction (RT-PCR) analysis
Total RNA was isolated using Trizol (Invitrogen, Carls-
bad, CA, USA) from the frozen tissue. First-strand
cDNA was synthesized from 5 μg of total RNA for each
sample using MMLV reverse transcriptase (MBI Fer-
mentas Inc, Ontario, Canada) and random hexamer pri-
mers, according to the manufacturer’s instructions.
Primers for chymase PCR (738 bp) were (forward) 5’-
CTG AGA GGA TGC TTC TTC CTG C-3’ and
(reverse) 5’-AGA TCT TAT TGA TCC AGG GCC G-3’
[23]. Primers for b-actin PCR (194 bp) were (forward)
5’-CCT GTA TGC CTC TGG TCG TAC C-3’ and
(reverse) 5’-TCT CGG CTG TGG TGG TGA AG-3’.
The PCR program for chymase was initiated by a 2 min
denaturation step at 94°C, followed by 35 cycles of 94°C
for 30 s, 63°C for 30 s and 72°C for 1 min, and a final
extension at 72°C for 5 min. PCR products were electro-
phoresed on a 1.5% agarose gel and visualized by ethi-
dium bromide staining. Densitometry was carried out
using a Bio-Rad ChemiDoc image acquisition system
and Quantity One (v4.6) quantitation software (Bio-Rad,
Hercules, CA, USA).
Western blotting analysis
Lung homogenates were prepared in lysis buffer, con-
taining 50 mM Tris-HCl, 150 mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 2 mM NaF, 2 mM EDTA,
0.1% SDS, and a protease inhibitor cocktail tablet
(Roche Applied Science, Indianapolis, USA). Equivalent
amounts of protein (30 μg) from each sample were
separated on 10% SDS-polyacrylamide gels, and then
transferred onto 0.45 μM polyvinylidene difluoride
(PVDF) membranes (Millipore, Bedford, USA). Primary
antibodies used were chymase monoclonal antibody
(1:1000; Chemicon, Temecula, USA), TGF-b1 polyclonal
antibody (1:500; Santa Cruz Biotechnology, Santa Cruz,
USA), Smad2/p-Smad2 polyclonal antibody (1:1000; Cell
Signaling, Beverly, USA), Smad3/p-Smad3 polyclonal
antibody (1:1000; Cell Signaling, Beverly, USA). The sig-
nals were developed using Super-Signal West Pico che-
miluminescent substrate (Pierce, Rockford, USA).
Statistical analyses
Values were expressed as mean ± SD. Statistical analysis
was carried out using one-way ANOVA, followed by
Tukey’s HSD test for post hoc multiple comparisons
(SPSS for Windows version 13.0, Chicago, USA). A sig-
nificant difference was accepted at P < 0.05.
Results
Chronic cigarette smoke exposure leads to pulmonary
artery remodeling and pulmonary hypertension in
hamsters
After four months of cigarette smoke exposure, thick-
walled pulmonary arterioles with inflammatory cell infil-
tration, intima hyperplasia, vascular smooth muscle
hypertrophy and deposition of collagen around vessel
wall were observed in the smoke-exposed hamster lungs
compared to the normal vascular structure in the con-
trol hamster lungs (Fig. 1a, H&E stain; Fig. 1b, Masson’s
trichrome stain). Concurrently, hamsters developed
emphysema-like airspace enlargement in lung periphery
after 4 months of cigarette smoke exposure (Fig. 1c).
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Figure 1 Cigarette smoke-induced changes in pulmonary vascular and alveolar morphology and right ventricular systolic pressure
(RVSP). (a) Representative hematoxylin and eosin (H&E) staining of small pulmonary vessels (original magnification × 40). (b) Representative
Masson’s trichrome staining of small pulmonary vessels (original magnification × 40). (c) Emphysema-like lesions in the lung after smoke
exposure (H&E staining, original magnification × 20). (d) Medial wall thickness (MWT) of pulmonary arterioles. (e) RVSP in hamsters. Con: control
group; CS: cigarette smoke-exposed group. Scale bars = 100 μm. Values are expressed as mean ± SD (n = 6). * P < 0.05, significant difference
from the control group.
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The medial wall thickness (MWT) of the arterioles,
which is an index of pulmonary artery remodeling, was
significantly increased after cigarette smoke exposure
(Fig. 1d; n = 6, P < 0.05). The changes in pulmonary artery
pressure were assessed by measuring RVSP via right heart
catheterization. In the smoke-exposed group, RVSP was
significantly higher than in the control group (31.50 ± 4.02
vs. 20.42 ± 1.54 mmHg; Fig. 1e, n = 6, P < 0.05).
Up-regulation of chymase expression in smoke-exposed
lungs
To determine whether chymase is involved in cigarette
smoking-induced pulmonary artery remodeling and
PAH, chymase protein and mRNA levels in the lungs of
the smoke-exposed hamsters and the control hamsters
were compared. Immunohistochemical analysis revealed
notable increase of chymase positive staining area in the
adventitia and hyperplastic intima of pulmonary arter-
ioles in the smoke-exposed hamster lungs as compared
with the control lungs (Fig. 2a). Furthermore, Western
blotting results showed that the relative protein levels
for chymase in smoke-exposed lung homogenates were
nearly 2.5 fold higher than in the control ones (Fig. 2b,
P < 0.05). To further examine chymase gene expression
at transcriptional level, the steady-state mRNA levels for
chymase and b-actin in lung tissue were analyzed by
RT-PCR. The accumulation of chymase mRNA in ham-
ster lungs was also significantly induced by cigarette
smoke exposure (Fig. 2c, P < 0.05). Together, these
results suggested that chymase expression was up-regu-
lated in cigarette smoke-exposed hamster lungs at both
mRNA and protein levels.
Figure 2 Changes in chymase protein and mRNA levels in hamster lungs. (a) Representative chymase immunohistochemical staining in
pulmonary arterioles (original magnification × 40). (b) Representative Western blotting analysis of chymase protein levels in hamster lungs. (c)
Representative RT-PCR analysis of chymase mRNA levels in hamster lungs. Con: control group; CS: cigarette smoke-exposed group. Scale bars =
100 μm. Data are expressed as mean ± SD (n = 3 for control group and n = 4 for smoke-exposed group). * P < 0.05, significant difference from
the control group.
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Increase in chymase-like activity in the lung after chronic
cigarette smoke exposure
Since chymase expression in the lung was up-regulated
by cigarette smoke exposure, we then measured the
changes in chymase-like and ACE activities in lung
homogenates. Results showed that both chymase-like
and ACE activities were increased by smoke exposure
(Fig. 3; n = 6, P < 0.05). The chymase inhibitor, chymos-
tatin, significantly reduced the cigarette smoke-induced
increase in chymase-like activity, whereas it had no
effect on ACE activity (Fig. 3; n = 6, P < 0.05).
Chymase inhibition attenuated cigarette smoke-induced
pulmonary artery remodeling and pulmonary
hypertension
As compared with hamsters exposed to cigarette smoke
alone, the hamsters exposed to cigarette smoke plus 1
mg/kg or 2 mg/kg chymostatin pre-administration
showed an attenuated induction of pulmonary artery
remodeling as indicated by MWT index (Fig. 4a, b; n =
6, P < 0.05). Similarly, chymostatin treatment also signif-
icantly inhibited the cigarette smoke-induced increase in
RVSP (Fig. 4c; n = 6, P < 0.05).
Figure 3 Changes of chymase-like and ACE activities after chymase inhibition with chymostatin in hamster lungs. (a) Chymase-like
activity. (b) ACE activity. Control: control group; CS: cigarette smoke-exposed group; 1 mg/kg Chymo: hamsters treated with 1 mg/kg
chymostatin alone; 2 mg/kg Chymo: hamsters treated with 2 mg/kg chymostatin alone; CS + 1 mg/kg Chymo: hamsters treated with cigarette
smoke plus 1 mg/kg Chymostatin; CS + 2 mg/kg Chymo: hamsters treated with cigarette smoke plus 2 mg/kg Chymostatin. Values are
expressed as mean ± SD (n = 6). * P < 0.05, significant difference from the control group. # P < 0.05, significant difference from the smoke-
exposed group.
Figure 4 Changes in the remodeling of pulmonary arterioles and RVSP after chymase inhibition with chymostatin. (a) Representative
van Gieson’s elastic staining of small pulmonary vessels (original magnification × 40). Scale bars = 100 μm. Con: control; CS: cigarette smoke
exposure; Chy: treatment with 2 mg/kg chymostatin alone; CS+Chy: treatment with smoke exposure plus 2 mg/kg chymostatin. (b) MWT of
pulmonary arterioles. (c) RVSP. Control: control group; CS: cigarette smoke-exposed group; Chymo: chymostatin treatment. Values are expressed
as mean ± SD (n = 6). * P < 0.05, significant difference from the control group. # P < 0.05, significant difference from the smoke-exposed group.
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Chymase inhibition reduced cigarette smoke-induced Ang
II accumulation and TGF-b1/Smad signaling activation
To determine the involvement of chymase pathway in
cigarette smoke-induced pulmonary hypertension, we
assessed Ang II concentration and TGF-b 1/Smad sig-
naling activation in hamster lungs. In the smoke-
exposed group, lung Ang II levels were significantly
higher than in the control group (602.17 ± 79.41 vs.
287.93 ± 31.25 pg/mg protein). Both 1 mg/kg and 2 mg/
kg chymostatin treatment significantly decreased the
lung tissue Ang II concentration as compared with the
smoke-exposed group (Fig. 5a; n = 6, P < 0.05).
TGF-b1, Smad2/p-Smad2, and Smad3/p-Smad3 were
detected by Western blotting analysis. Results showed
that TGF-b1, p-Smad2, and p-Smad3 protein levels were
markedly increased in the smoke-exposed lungs com-
pared to the control lungs (Fig. 5b). Blockade of chy-
mase with chymostatin resulted in a significant
reduction of TGF-b1, p-Smad2 and p-Smad3 as com-
pared with the smoke-exposed group. In contrast, chy-
mostatin exerted no inhibitory effects on the total
Smad2 and Smad3 protein levels. Taken together, these
results suggest that cigarette smoke exposure causes
enhanced Ang II accumulation and activation of TGF-
b1/Smad signaling pathway, which could be suppressed
by chymase inhibition with chymostatin.
Discussion
In this study, we demonstrated the potential role of chy-
mase in cigarette smoke-induced pulmonary artery
remodeling and pulmonary arterial hypertension. In the
hamster model studied here, chronic smoke exposure
induced intima proliferation, smooth muscle hypertro-
phy and collagen deposition in pulmonary arterioles,
which may lead to increased RVSP. Our results indi-
cated that chronic cigarette smoke exposure significantly
increased chymase synthesis and activity in the lung,
and that chymase inhibition with chymostatin effectively
attenuated the smoke-induced pathophysiological
changes in pulmonary arterioles, possibly through inhi-
biting the conversion of AngII and the activation of
TGF-b1/Smad signaling pathway.
Numerous studies have reported that chymase, acting
as an important component of the local renin-
Figure 5 Changes in Ang II levels and TGF-b1/Smad signaling activation in hamster lungs. (a) Ang II levels. Values are expressed as mean
± SD (n = 6). (b) Protein levels of TGF-b1, b-actin, p-Smad2, Smad2, p-Smad3 and Smad3 measured by Western blotting analysis. Images are
representative of three independent experiments. Relative protein levels were assessed by densitometry. Control: control group; CS: cigarette
smoke-exposed group; Chymo: chymostatin treatment. * P < 0.05, significant difference from the control group. # P < 0.05, significant difference
from the smoke-exposed group.
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angiotensin system (RAS), is activated in vascular dis-
ease conditions, such as hypertension and atherosclero-
sis [24,25]. High levels of chymase have been found in
both spontaneously hypertensive rats and monocrota-
line-induced PAH rats [7,10]. Cigarette smoking is a
major risk factor for pulmonary airway and vascular dis-
eases [26,27]. In smokers, mast cells containing chymase
in peripheral airways may contribute to the relationship
between air trapping and airway inflammation [16]. In
in vitro studies, mast cells exposed to cigarette smoke
condensate revealed a marked increase in chymase tran-
script levels [28]. In the present study, we found that
chronic cigarette smoke exposure significantly up-regu-
lated chymase expression at both mRNA and protein
levels in hamster lungs, which was associated with
increased artery remodeling, emphysema-like changes
and RVSP elevation. ACE and chymase-like activities in
the lung were also increased in response to cigarette
smoke exposure. As indicated by chymase immunohisto-
chemistry, chymase-containing mast cell accumulation
and chymase release into the interstitial lung tissue
might contribute to the increase of chymase expression
in hamster lungs.
Given the potential role of chymase in pulmonary
hypertension, we sought to test whether the well-studied
chymase inhibitor chymostatin can reverse the damaging
effects of cigarette smoke. The results showed that chy-
mostatin administration significantly reduced the smoke-
induced increase in chymase activity but had no effect on
ACE activity, suggesting that chymostatin was mainly act-
ing through the inhibition of chymase in the lung. Recent
studies have demonstrated that chymase plays a func-
tional role in ACE-independent generation of AngII,
which occurs immediately after its release into the inter-
stitial tissues after vascular injury [5,9,29]. In our results
we could show a two fold increase in lung AngII levels
after four months of cigarette smoke exposure, which
was significantly reduced by chymase inhibition with chy-
mostatin. Chymostatin treatment also reduced pulmonary
arteriolar hypertrophy and RVSP as compared with the
smoke-exposed hamster lungs. These results indicate that
chymase might be an alternative pathway for local pul-
monary AngII formation and play an important role in
the cigarette smoke-induced PAH.
The roles for chymase in disease progression are not
limited to AngII generation; chymase also has wide-
spread effects independent of AngII formation, including
activation of TGF-b1 and angiogenesis [14,15]. Previous
studies have reported that chymase activates latent
TGF-b to form mature TGF-b and increase collagen
production [30,31]. The active form of TGF-b exerts
many biological actions in the pathogenesis of lung dis-
ease, including the stimulation of fibroblast proliferation,
extracellular collagen deposition, cell proliferation, and
angiogenesis [32,33]. Smads are the major transducer of
TGF-b signaling pathway in lung fibrosis. Mice exposed
to cigarette smoke up to 6 months showed increased p-
Smad2 protein levels in the lung, indicating enhanced
TGF-b downstream signaling by smoke exposure [34].
Chymase has recently been reported to activate the
TGF-b1/Smad signaling pathway in rat cardiac fibro-
blasts [11]. Chymase inhibition can decrease TGF-b1
transcription levels and prevent cardiac fibrosis in ani-
mal models [35,36]. In the present study, TGF-b1, p-
Smad2, p-Smad3 protein levels are markedly up-regu-
lated in the smoke-exposed hamster lungs, which could
be all reduced by chymase blockade with chymostatin.
These results imply that chymase activation and upregu-
lation by chronic smoke exposure might also enhance
the TGF-b1/Smad signaling pathway and promote pul-
monary artery remodeling in hamster lungs.
One limitation of this study is that chymostatin is
known to inhibit other serine proteases, such as cathe-
psin G which is also capable of generating Ang II from
Ang I [37] and cathepsin D which can also activate
latent TGF-b1 [38]. So the use of chymostatin cannot
unequivocally indicate the relative contribution of differ-
ent serine proteases in the generation of Ang II and the
activation of TGF-b1. Nevertheless, as established in lit-
erature, chymostatin was found to be much more potent
as inhibitors of chymase than of cathepsin G and cathe-
psin D activities [39,40]. Furthermore, chymase is the
predominate enzyme for ACE-independent production
of Ang II in vascular tissues of humans, monkeys, dogs,
and hamsters [41,42]. Thus our results are likely to
reflect roles of chymase in cigarette smoke-induced
PAH in hamsters.
Conclusions
In summary, our data reveal that chymase activity and
expression was significantly increased in chronic cigar-
ette smoke-induced pulmonary hypertensive hamsters
with elevated RVSP and remodeling of pulmonary arter-
ioles. In addition, chymase inhibition with chymostatin
significantly decreased not only RVSP but also AngII
levels and TGF-b1/Smad signaling pathway activation in
smoke-exposed lungs. These results suggest that the
capability of activated chymase to induce Ang II forma-
tion and TGF-b1 signaling may be part of the mechan-
ism for smoking-induced pulmonary vascular
remodeling. Thus, our study implies that blockade of
chymase might provide benefits to PAH smokers.
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